Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 104479

Result Summary for 104479

Result Summary

Protocol ID:	104479
Clinical Study ID:	104479
Official Title:	Phase IIIb, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 VLP/AS04 vaccine administered intramuscularly at 0, 1, 6 months in healthy Indian female subjects aged 18–35 yrs
Phase:	phase 3
Study Indications or Diseases:	Papillomavirus Vaccines
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Bhatla N et al. (2010) Immunogenicity and safety of human papillomavirus- 16/18 AS04- adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res. 36(1): 123-132. Verstraeten T et al. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 26(51):6630–6638.